Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07086651 · ClinicalTrials.gov registry record
A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 1,300
- Enrollment target
NCT07086651: Completed study, sponsored by Pfizer.
NCT07086651 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1,300 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07086651 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1,300 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about how long apalutamide and enzalutamide are taken by men to treat mCSPC. Prostate cancer is one of the most common cancers in men. The prostate is a gland in the male body that helps make semen. Metastatic cancer is a cancer that has spread to other parts of the body. Castration-sensitive prostate cancer means the cancer is being controlled by keeping the testosterone levels as low as would be expected if the testicles were removed by surgery. This is a real-world study, not a clinical study. This means that researchers will look at what happens when men receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information from cancer clinics (Flatiron Health electronic health records). The study will include patients' information from the database for men who: * Were identified to have mCSPC. * Started treatment with apalutamide or enzalutamide (index date) for mCSPC. * Were 18 years of age or older on the index date. Men in this study will be taking apalutamide or enzalutamide for treatment of their mCSPC. The study will compare how long men take apalutamide or enzalutamide. This study will use patient information from cancer clinics. Information from start of apalutamide or enzalutamide treatment until information is available in the database will be used to describe how long patients receive treatment.
Primary Outcome
Treatment duration will be defined as the time from index date to the discontinuation (i.e., addition of subsequent treatment, treatment gap of 90 days, death) of the index treatment for any reason. Patients without an event will be censored on the date of last confirmed clinical activity.
Interventions
- DRUG Apalutamide
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,300 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2025-10-31 |
What the finished NCT07086651 record still lists
NCT07086651 is an observational study that tracks outcomes without assigning an intervention. Its 1,300 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Apalutamide is the first listed.
NCT07086651 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07086651 about?
NCT07086651 is a clinical study titled "A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)". The purpose of this study is to learn about how long apalutamide and enzalutamide are taken by men to treat mCSPC. Prostate cancer is one of the most common cancers in men. The prostate is a gland in the male body that helps make semen. Metastatic cancer is a cancer that has spread to other parts o...
What is the current status of trial NCT07086651?
This trial is currently completed. The enrollment target is 1,300 participants. The study started on 2025-07-21. Estimated completion is 2025-10-31.
What interventions are being tested in trial NCT07086651?
The interventions under investigation include: Apalutamide (DRUG), Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT07086651?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
- NCT04792684 · 1,300 participants
Collection of Samples USOPTIVAL Study
- NCT05166694 · 1,300 participants · NA
Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
- NCT05282654 · 1,300 participants · NA
Real-time Symptom Monitoring Using ePROs to Prevent Adverse Events During Care Transitions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI